Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment

Inclusion Criteria: * Employees, family members, and patients with positive C13 breath test in our hospital; * Has received one or more previous Helicobacter pylori eradication therapy (no use of cefuroxime or tetracycline), and the result is still positive by C13 breath test; * Willing to undergo gastroscopy and HP cultivation and identification; * Age 18-70, gender unlimited; * Willing to participate in and cooperate with the study, and willing to sign the informed consent. Exclusion Criteria: * Drugs that may affect the study results, such as PPI, H2 blockers, bismuth agents, antibiotics, etc. were taken in the 4 weeks before enrollment; * Patients with gastrointestinal malignancy tumor; * Patients with gastrinoma; * After gastric or esophageal surgery; * Suffers from serious diseases of the heart, lung, kidney, liver, blood, nervous system, endocrine system or mental system; * Patients with contraindications or previous allergic reactions to the drugs used in this study; * Pregnant or breastfeeding women; * Patients with other medical conditions that may increase the treatment side effects; * Those who cannot give informed consent; * Has participated in other drug trials within 3 months; * Not considered suitable for participants by the investigator.